If MIN 101 says the primary completion date is in 2020, that’s pretty standard for a phase 3. Even though individual participants aren’t taking it that long, people start at different times. Like, they might begin with 100 people now but have 1,000 over the course of the next 2 years. Then usually after phase 3 they will take at least 6 months or a year to complete analysis and make an application to the FDA to accept their drug. So if they are finishing in 2020, the soonest it might be available would likely be 2021 or 2022.
The makers of Lumateperone have said they intend to submit their drug for FDA approval in mid 2018. They have some bipolar trials ending around then so it’s possible they are waiting for data on those. After they submit it, it might take 6 months or a year … unless the FDA wants more studies, then longer.
Naben’s study completion date is mid-2019. So that might be approved by 2020-2021.